In NSCLC, up to 50% in adenocarcinomas of Asian patients harbor activating mutations of EGFR [6], and approximately 20% of squamous cell carcinomas have fibroblast growth factor receptor 1 (FGFR1) amplifications [7]. The gene discussed is FGFR1; the disease is squamous cell carcinoma.